Latest Breaking News On - Daniele fontana - Page 1 : vimarsana.com

Sintetica® US Selects FFF Enterprises Inc as the Exclusive Distributor for Lidocaine Hydrochloride Injection

Sintetica® US Selects FFF Enterprises Inc as the Exclusive Distributor for Lidocaine Hydrochloride Injection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Frank mulleryDaniele fontanaMichelle valenzuelaPatrickm schmidtNufactor incMarketing communicationsEnterprises incLidocaine hydrochloride injectionHelping healthcare careRightnow inventory

Sintetica SA: Sintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

Lidocaine hydrochloride is a short-acting amide-type local anesthetic with a rapid onset and short duration of action and contains no preservatives. MENDRISIO, Switzerland and PRINCETON

Switzerland generalNew jerseyUnited statesPrnewswire sinteticaNicola caronzoloDaniele fontanaFrank mulleryBusiness developmentLidocaine hydrochloride injectionLidocaine injectionSintetica chief executive officerFull prescribing information

Sintetica establishes US entity

MENDRISIO, Switzerland, Oct. 14, 2022 /PRNewswire/ Sintetica, a Swiss pharmaceutical company headquartered in Mendrisio specializing in injectables in the field of pain therapy, has taken

New jerseyUnited statesSwitzerland generalPrnewswire sinteticaKostenloser wertpapierhandelFrank mulleryDaniele fontanaNicola caronzoloViropharma incTeva pharmaceuticalsMylan institutionalChief commercial officer

Börse Express - Sintetica establishes US entity

Sintetica, a Swiss pharmaceutical company headquartered in Mendrisio specializing in injectables in the field of pain therapy, has taken another important and significant step in its 100-year growth strategy. On July 14, 2022 Sintetica established its subsidiary Sintetica US, headquartered in Princeton, New Jersey, headed by leading pharma expert F.

New jerseyUnited statesSwitzerland generalFrank mulleryDaniele fontanaNicola caronzoloViropharma incTeva pharmaceuticalsMylan institutionalChief commercial officer

Sintetica SA: Harrow Announces U S FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly

San diegoUnited statesSwitzerland generalKostenloser wertpapierhandelJamie webbMarkl baumNicola caronzoloDaniele fontanaDeb hollidayExchange commissionAmerican society of cataractOld international pharmaceutical company sinteticaInstitute for safe medication practicesDrug administrationHolliday communications incFirst approved use